PharmaCorp Rx (PCRX) investor relations material

Industry overview and growth drivers

• Pharmacy sector is recession-resilient, driven by essential healthcare spending and government funding.

• Aging Canadian population increases prescription demand, especially after age 45 and 65.

• Regulatory changes expand pharmacists' scope, creating new revenue streams.

• High patient loyalty and recurring relationships support predictable revenue.

• Demographic trends and rising prescription use provide strong industry tailwinds.

Business model and competitive advantages

• Operates a buy-integrate-operate model focused on acquiring, optimizing, and managing pharmacies across Canada.

• Holds exclusive right of first refusal on 1,100+ PharmaChoice Canada stores, ensuring unique pipeline access.

• Retail collaboration agreement with McKesson Canada enhances deal flow and operational capabilities.

• Acquisition criteria include pharmacies with $2M+ annual revenue and $350K+ adjusted EBITDA.

• Co-ownership loan program aligns interests and supports pharmacist retention and recruitment.

Acquisition and integration strategy

• Targets pharmacies with strong script counts and offers flexible exit options for sellers, including equity upside and legacy preservation.

• Post-acquisition strategy focuses on front shop optimization, margin improvement, and workflow technology integration.

• Aims for 7.5–15% adjusted EBITDA lift over three years post-acquisition.

• Integration playbook includes 30-day stabilization, six-month optimization, and one-year full integration for scalable growth.